Agentix Corp
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of novel therapeutics to treat metabolic diseases in the United States. It develops AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, … Read more
Agentix Corp (AGTX) - Total Liabilities
Latest total liabilities as of December 2025: $3.50 Million USD
Based on the latest financial reports, Agentix Corp (AGTX) has total liabilities worth $3.50 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Agentix Corp - Total Liabilities Trend (2013–2025)
This chart illustrates how Agentix Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Agentix Corp Competitors by Total Liabilities
The table below lists competitors of Agentix Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Panbela Therapeutics Inc
NASDAQ:PBLA
|
USA | $23.34 Million |
|
Dalrada Financial Corp
PINK:DFCO
|
USA | $30.58 Million |
|
UTD TECHNOLOGIES
HM:UTC1
|
Germany | €101.96 Billion |
|
Gossan Resources Ltd
V:GSS
|
Canada | CA$139.75K |
|
Intra Energy Corporation
AU:IEC
|
Australia | AU$1.12 Million |
|
WarpSpeed Taxi Inc
PINK:WRPT
|
USA | $121.80K |
|
RYDER SYSTEM - Dusseldorf Stock Exchang
DU:RYD
|
Germany | €13.44 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Agentix Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 547.90 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Agentix Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Agentix Corp (2013–2025)
The table below shows the annual total liabilities of Agentix Corp from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $3.20 Million | +20.17% |
| 2024-03-31 | $2.67 Million | +6.22% |
| 2023-03-31 | $2.51 Million | +3523.36% |
| 2022-03-31 | $69.29K | -44.96% |
| 2021-03-31 | $125.88K | 0.00% |
| 2020-03-31 | $125.88K | +127.22% |
| 2019-03-31 | $55.40K | -23.24% |
| 2018-03-31 | $72.17K | +8195.75% |
| 2017-03-31 | $870.00 | -88.20% |
| 2016-03-31 | $7.37K | -62.30% |
| 2014-03-31 | $19.55K | +95.51% |
| 2013-03-31 | $10.00K | -- |